Streetbeat News

SNANF

Sona Nanotech Inc.

Industry

Dimension Stone Mining and Quarrying

Open

0.23

Mkt cap

21M

Volume

High

0.23

P/E Ratio

-9.55

52-wk high

0.38

Low

0.19

Div yield

N/A

52-wk low

0.16

Sona Nanotech Inc.'s CEO, David Regan, will present at the Investor Summit Virtual on March 11, 2025. The company is advancing a novel cancer immunotherapy and is nearing human trials.

Portfolio Pulse from

March 06, 2025 | 12:45 pm

Sona Nanotech Inc. will present its findings on targeted hyperthermia therapy using gold nanorods at the 19th Canadian Melanoma Conference. The study shows promising results in inducing immunogenic cell death in tumors.

Portfolio Pulse from

February 12, 2025 | 1:30 pm

Sona Nanotech Inc announced the publication of its preclinical cancer therapy study in Frontiers in Immunology, highlighting its patented gold nanorod technology for Targeted Hyperthermia Therapy (THT).

Portfolio Pulse from

February 01, 2025 | 4:15 pm

Sona Nanotech is making strides in cancer therapy with its innovative use of gold nanorods to combat 'cold tumors,' a challenge that traditional immunotherapies like Merck's Keytruda have struggled to address.

Portfolio Pulse from

January 31, 2025 | 3:45 pm

Sona Nanotech Inc has published promising preclinical study results for its Targeted Hyperthermia Therapy (THT) in a leading journal, highlighting potential advancements in cancer treatment.

Portfolio Pulse from

January 22, 2025 | 3:15 pm

Sona Nanotech Inc. has published the findings of its preclinical studies on Targeted Hyperthermia Therapy for breast cancer and melanoma in the journal Frontiers in Immunology. The study provides a comprehensive analysis of the immunity activated by the therapy.

Portfolio Pulse from

January 13, 2025 | 2:30 pm

Sona Nanotech Inc. has announced strong efficacy results from its third preclinical study of its Targeted Hyperthermia Therapy (THT) using gold nanorods for treating solid cancer tumors. The study focused on colorectal cancer, showing promising results and plans for a first-in-human feasibility study.

Portfolio Pulse from

December 11, 2024 | 2:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.